PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma

Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act.

RALEIGH, N.C., May 13, 2021 (GLOBE NEWSWIRE) — PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today an innovative tokenization solution using Synoma®, PRA’s proprietary technology that allows for the generation of enhanced evidence for drug development. PRA’s solution makes it possible to connect clinical trial data and secondary data sets with privacy at the forefront. Today, three large pharmaceutical companies, along with several other pharmaceutical and biotech companies of all sizes, are using Synoma to link data and conduct analyses across their drug development portfolios.

“Data of all types is widely available from dozens of sources. The missing link, however, is the ability to connect clinical trial data to the insights from real-world data – enabling researchers to understand what is happening outside and after a study in a way that protects privacy,” said Kent Thoelke, Executive Vice President and Chief Scientific Officer, PRA Health Sciences. “Tokenization and linking is the approach researchers can use to glean the greatest insights into drug safety and effectiveness over time.”

PRA can partner with a variety of tokens to multiple sources of information – making it possible to incorporate broader sets of real-world data and revolutionize evidence generation and insights as envisioned by the 21st Century Cures Act.

“Tokenization of siloed patient data sets will be a game-changer for clinical researchers and drug developers,” said Jane Quigley, Senior Vice President, Digital Health, PRA Health Sciences. “Through our acquisition of Symphony Health and partnership with other data sources, we have enabled scientists and research teams to more intelligently evaluate a wider set of data to inform clinical trial protocols, leverage real-world data as eSource, conduct advanced feasibility, speed enrollment and, ultimately, bring novel and differentiated therapies to market faster.”

Contact us to learn more about how Synoma can be applied to clinical studies.

About PRA Health Sciences

PRA Health Sciences is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, Africa, Australia and the Middle East and more than 19,000 employees worldwide. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 95 drugs. To learn more about PRA, please visit


MEDIA INQUIRIES: Laurie Hurst, Sr. Director, Communications and Public Relations | +1 (919) 786-8435

Previous Article

مؤتمر الذكاء العالمي الخامس: في طليعة الابتكار

Next Article

‫ تجمع تمويلًا بقيمة 130 مليون دولار أمريكي لتوسيع نطاق منصتها الصحية الرقمية من أجل رعاية وأبحاث أفضل Huma

Related Posts

The Indonesia Ministry of SOEs Supports PLN’s Breakthrough to Accelerate the Clean Energy Transition in Indonesia

JAKARTA, Indonesia, Oct. 26, 2022 /PRNewswire/ — PT PLN (Persero) today reaffirmed its committed to support the Indonesian government’s program to achieve the Net Zero Emission target by 2060 through various strategies, such as the development of new and renewable energy (RE)-based power plants, dieselization programs, and the retirement of steam power plants (PLTU). Vice […]

University of Toronto’s Reach Alliance expands its network by partnering with academic institutions in Africa, Asia and Australia

— Global initiative brings together researchers and practitioners from across disciplines and around the world to accelerate the achievement of the UNs’ Sustainable Development Goals — TORONTO, July 20, 2022 /PRNewswire/ — The Reach Alliance announces partnerships with four leading universities, including the University of Cape Town (South Africa), Ashesi University (Ghana), Singapore Management University (Singapore) and […]

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BurgerFi International, Inc. f/k/a Opes Acquisition Corp. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BFI, OPES

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BurgerFi International, Inc. f/k/a Opes Acquisition Corp. (NASDAQ: BFI, OPES) between December 17, 2020 and November 15, 2022, both dates inclusive (the “Class Period”), of the important June 5, 2023 lead plaintiff […]